Investor Series Immunology & Cardiovascular June 26, 2020

Page created by Michele Mack
 
CONTINUE READING
Investor Series Immunology & Cardiovascular June 26, 2020
Investor Series
Immunology & Cardiovascular
June 26, 2020
Investor Series Immunology & Cardiovascular June 26, 2020
Forward Looking Statement and Non-GAAP Financial Information

This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking
statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated as a result of various important factors, including those discussed in
the Company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are
available on the SEC’s website, on the Bristol-Myers Squibb website or from Bristol- Myers Squibb Investor Relations.

In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied
upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements
at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

This presentation may include certain non-generally accepted accounting principles (“GAAP”) financial measures that we
use to describe our company’s performance. The non-GAAP information presented provides investors with additional
useful information but should not be considered in isolation or as substitutes for the related GAAP measures. Moreover,
other companies may define non-GAAP measures differently, which limits the usefulness of these measures for
comparisons with such other companies. We encourage investors to review our financial statements and publicly-filed
reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial
measures and a reconciliation to the most directly comparable GAAP financial measure are available on our website at
bms.com/investors. Note that pro forma revenues in this presentation assume that the Company’s acquisition of Celgene
Corporation and the Otezla® divestiture occurred on January 1, 2019. Also note that a reconciliation of certain pro forma
measures, however, is not provided due to no reasonably accessible or reliable comparable GAAP measures for such pro
forma measures and the inherent difficulty in forecasting and quantifying such pro forma measures that are necessary
for such reconciliation.
Investor Series Immunology & Cardiovascular June 26, 2020
Investor Series

                                Giovanni Caforio
                                Chairman and
                                Chief Executive Officer

        Investor Series Day 3                             Not for Product Promotional Use   3
Investor Series Immunology & Cardiovascular June 26, 2020
Deep portfolio for continued innovation across key therapeutic
areas of focus
                                    Immuno-Oncology          Hematology         Immunology & CV

Inline
Brands

New
Launches                                              liso-cel   ide-cel   CC-486              TYK2i
                                1L Lung, CM-9ER

                       Metastatic disease                  Multiple myeloma          Inflammatory            Other
Multiple                                                                                 Bowel           auto-immune
                                                          B-cell malignancies           Disease             diseases
LCMs                  Early stage disease
                                                           Myeloid diseases           UC - Crohn’s   Lupus - Psoriatic arthritis

Next                 Relatlimab                            CELMoD agents                    Factor XIa inhib
Medicines
              Bempeg (NKTR-214)                        T-cell engager (TCE)                             Cendakimab

Next Wave   >20 assets with proof of concept decisions over the next three years
            Investor Series Day 3                                                                          Not for Product Promotional Use   4
Investor Series Immunology & Cardiovascular June 26, 2020
Immunology & CV Development

                               Samit Hirawat
                               Executive VP
                               Chief Medical Officer
                               Global Drug Development

       Investor Series Day 3                             Not for Product Promotional Use   5
Investor Series Immunology & Cardiovascular June 26, 2020
Potential first- and/or best-in-class late stage assets with
   significant life cycle management opportunities
         Immuno-Oncology                             Hematology                            Cell Therapy                    Immunology & Fibrosis                        Cardiovascular
         Asset          Tumor Type                Asset          Indication             Asset          Indication                Asset           Indication            Asset           Indication

                           Bladder        Rebloyzl(2)                MDS            ide-cel(3)              MM                                   Psoriasis        FXIa               Thrombotic
                         Esophageal       (EMA)                      MF             (BCMA CAR T)                                                   PsA            Inhibitor(4)        Disorders
                           Gastric                                                                                         TYK2                     UC
                        Glioblastoma                                  MM                                  DLBCL
                                          Iberdomide                                                                       Inhibitor                CD
Opdivo,                Hepatocellular     (CELMoD agent)              SLE           liso-cel                FL
                                                                                                                                                   SLE
Yervoy                  Head & Neck                                                 (CD19 CAR T)           CLL
                                                                                                                                                    LN
(anti PD-1,              Melanoma
                                          CC-486                     AML                                   MCL
 anti CTLA-4)          Mesothelioma       (DNMTi)                    AITL                                                  Zeposia                   UC
                            NSCLC                                                   orva-cel                MM
                          Prostate                                                  (BCMA CAR T)                           (S1P agonist)             CD
                                          CC-92480                    MM
                            Renal         (CELMoD agent)
                                                                                    bb21217(3)                             Cendakimab               EoE
                                                                                    (BCMA CAR T)            MM             (anti-IL-13)
                                          CC-93269                    MM
Relatlimab               Melanoma         (BCMA TCE)
(anti-LAG3)                                                                                                                HSP47                  Fibrosis

                          Bladder                                                                                          Pegbelfermin
Bempegaldesleukin(1)                                                                                                                               NASH
(IL-2)
                         Melanoma                                                                                          (FGF-21)
                           Renal
                                                MF = myelofibrosis; MM = multiple myeloma; AML = acute myeloid leukemia; AITL = angioimmunoblastic T-cell lymphoma; PsA = Psoriatic arthritis;
                                                UC = ulcerative colitis; CD = Crohn’s disease; SLE = systemic lupus erythematosus; LN = lupus nephritis
                        Investor Series Day   3                                                                                                                  Not for Product Promotional Use 6
                                                1) In partnership with NEKTAR Therapeutics, 2) in partnership with Acceleron, 3) partnership with bluebird bio, 4) In partnership with J&J
Investor Series Immunology & Cardiovascular June 26, 2020
Substantial evolution of our immunology portfolio over the
next 3 years
                               2020                               2021                           2022+

         Zeposia                                 TYK2i                          TYK2i
         Multiple Sclerosis                      Psoriasis                      Lupus nephritis
          FDA and EU Approval                   Ph3 POETYK PSO-2 (IM011-047)   Ph2 PAISLEY-LN (IM011-073)

         Zeposia                                 TYK2i                          TYK2i
         Ulcerative Colitis                      Psoriasis                      Crohn’s Disease
         Ph3 TrueNorth                           Ph3 (IM011-066) Japan          Ph2 LATTICE (IM011-023)
          Positive Topline

                                                 TYK2i                          Zeposia
         TYK2i                                   Systemic lupus erythematosus   Crohn’s Disease
         Psoriatic Arthritis                     Ph2 PAISLEY (IM011-021)        Ph3 Yellowstone program
         Ph2 (IM011-084)

                                                 TYK2i                          TYK2i
         TYK2i                                   Ulcerative Colitis             Psoriasis
         Psoriasis                               Ph2 LATTICE (IM011-024)        Ph3 (IM011-065) China-Asia
         Ph3 POETYK PSO (IM011-046)

                                                                                Cendakimab
                                                                                Eosinophilic Esophagitis
                                                                                Ph3 (target start late 2020/early 2021)
Registrational

Signal Seeking

                         Investor Series Day 3                                                               Not for Product Promotional Use   7
Investor Series Immunology & Cardiovascular June 26, 2020
TYK2i has a novel mechanism of action that allows
differentiated effects from JAK inhibitors
     BMS-986165                                                                                        TYK2 inhibition has downstream effects on IL-12,
                                                                    ATP-binding                        IL-23, and Type I interferon, key cytokines in
                                                                     active site                       immune-mediated disease pathogenesis
                                                                                                       BMS-986165 targets a novel pseudokinase domain,
                                                                                                       which offers selective inhibition of
                                                                                                       IL-23, IFNa and IL-12
                                        TYK2
                                        TYK2
                                                                                                                                   Cellular IC50 (nM)1
                                                                         Active
                                                                         domain                                         IL-23       IFNa        IL-12                   EPO
     Regulatory domain
                                                                                                          Agent      (TYK2/JAK2) (TYK2/JAK1) (JAK1/JAK3)              (JAK2)
   (pseudokinase domain)
                                                                                                      BMS-986165         8            5          623                >10,000

IC50=half-maximal inhibitory concentration; IFN=interferon; IL=interleukin; JAK=Janus kinase; TYK=tyrosine kinase.
1. Gillooly K et al. Poster presentation at ACR/ARHP 2016. Abstract 11L.

                            Investor Series Day 3                                                                                               Not for Product Promotional Use   8
Investor Series Immunology & Cardiovascular June 26, 2020
TYK2 inhibition: In-Vitro data suggests differentiated
profile versus JAKs
                                                                                                                  Assay IC50 (nM)1
                                                                                                    Active site                 Active site                   Active site                  Active site

                            BMS-986165 binding site             TYK2                       TYK2                         JAK1                           JAK2                      JAK3
                                                                 TY                         TY                           TY                             TY                        TY
                                                                  K2                         K2                           K2                            K2                          K2

                                                        Regulatory domain                    Active domain              Active domain                  Active domain               Active domain

                                                         TYK2 regulatory                TYK2 active
                         Inhibitor                                                                                       JAK1                          JAK2                         JAK3
                                                            domain                        domain
   1                    Tofacitinib                                nd                         489                          15                           77                            55
   2                    Baricitinib                                nd                          61                           4                            7                           787
   3                     Filgotinib                                nd                        2600                         363                          2400                        >10000
   4                  Upadacitinib                                 nd                        4690                          47                           120                         2304
   5                   PF-06700841                                 nd                          23                          17                           77                          6494
   6                   PF-06826647                                 nd                          17                         383                           74                         >10000
   7                  BMS-986165                                  0.2                      >10000                      >10000                      >10000                         >10000

IC50=half-maximal inhibitory concentration; JAK=Janus kinase; nd=not determined; TYK=tyrosine kinase
Wrobleski ST et al. J Med Chem. 2019;62(20):8973-8995; Burke JR et al. Sci Transl Med. 2019;11(502); Winthrop KL. Nat Rev Rheumatol. 2017;13:234-243

                           Investor Series Day 3                                                                                                                  Not for Product Promotional Use        9
Investor Series Immunology & Cardiovascular June 26, 2020
BMS-986165 has demonstrated proof-of-concept for TYK2
inhibition in Psoriasis
                                                                                              Ph 2 takeaways
Response rate for key products from Ph 3 trials (PASI-75)
% patients at week 12 or 16                                                                   Robust clinical efficacy
  100                                                                                         • Consistent dose response observed with sustained
             Biologic                                                  91
             Small molecule        82
                                                 89       89                                    efficacy after discontinuation of dosing
   80
            67
                        71                                                             69     • Efficacy in both biologic-naïve and -exposed
   60
                                                                                                subjects

   40
                                                                             33
                                                                                      Ph2     Validation of target and MoA
   20
                                                                                              • Reduction in expression of genes of the
                                                                                                IL-23/IL-12 and type I IFN pathways
     0
         Stelara    Humira Cosentyx             Taltz   Skyrizi   Tremfya   Otezla   TYK2i^   • No change in JAK1, JAK2 or JAK3 biomarkers
Target   IL-12/23       TNF             IL-17                  IL-23        PDE4     TYK2i    • No dyslipidemia, liver abnormalities,
                                                                                                lymphopenia, or thrombotic events associated
Note: ^ TYK2i data is from Ph 2, 3mg BID                                                        with JAK inhibitors
Source: FDA product labels, TYK2i Phase 2 data, EvaluatePharma

                              Investor Series Day 3                                                                             Not for Product Promotional Use   10
Phase 3 Trial designs for POETYK1 and 2

                                                                                                                               BMS-986165                                                    Long-term
Adults with

                                              IM011-046
                                                                        Placebo                                                              BMS-986165                                       rollover
moderate to                       Randomize                                                                                                                                                    study
severe psoriasis                                                                                               ≥PASI-50                          Apremilast 30 mg BID
                                                            Titrate*               Apremilast 30 mg BID
No concomitant
systemic or
TYK2 inhibition has potential to impact a variety of diseases

 Core Indication                                  Strength of Evidence         TYK2 Signaling Pathways           Next Data Readout

                                             Clinical Preclinical Genetic
                                            Validation  Models    Validation

 Psoriatic Arthritis                                                                    IL-23                      Ph2 study (2H 2020)

 Systemic Lupus Erythematosus                                                  IL-12    IL-23    Type I IFN         Ph2 study (2021)

 Lupus Nephritis                                                               IL-12*   IL-23*   Type I IFN         Ph2 study (2022+)

 Ulcerative Colitis                                                            IL-12*   IL-23                 Ph 2 Mod to severe UC (2021)

 Crohn’s Disease                                                               IL-12*   IL-23                 Ph 2 Mod to severe CD (2022+)

* Not yet validated pathways

                          Investor Series Day 3                                                                       Not for Product Promotional Use   12
Zeposia: Potential to be a differentiated oral medicine in UC
                    Autoreactive
                    lymphocyte
                   migration to gut                   • Ozanimod modulates select S1P
                                                        receptors reducing reach of
                                                        autoreactive lymphocytes to the gut
                     ozanimod

  First oral S1P to demonstrate benefit in              Favorable safety profile reflected in best-in-
  moderate to severe UC in a Ph 3 study                 class MS label
  • Primary endpoints of clinical remission in         • No black box warning
    induction and in maintenance (p
Zeposia Ph 3 study ongoing in Crohn’s Disease

                                                                                          Zeposia in CD
STEPSTONE (Ph 2)1                                                                                     YELLOWSTONE program (Ph 3 Study Design)
                                                                                                      Adults with moderately to severely active CD

                              Endoscopic Response (SES-CD decrease ≥50%)                                               N = 450

                                                                                                                                        Zeposia responders or remitters are re-
                                                                                                                                         randomized 1:1 to Zeposia or Placebo
                                             at Week 122                                                               Zeposia
                         60
                                                                                                    Study
                                                                                                                       N = 225
                         50                                                                         3201                                                                                 Zeposia
  % of Patients (wk12)

                                                                                                                       Placebo
                         40
                                                                                                                       N = 450
                         30
                                                     28.1%
                                 23.2%                                                                                 Zeposia                                                           Placebo
                                                                         18.9%                      Study
                         20
                                                                                                                       N = 225
                                                                                                    3202
                         10                                                                                             Placebo
                         0                                                                                              12 wk
                                 Overall        Biologic naïve          Biologic                                    induction study                                               52 wk maintenance study
                                 (n=69)             (n=32)            experienced
                                                                         (n=37)                     Primary endpoints:
                                                                                                    • Induction studies: Week 12 Clinical remission
                                                                                                    • Maintenance study: Co primary @ Week 52 Clinical remission and endoscopic response
                         Mean CDAI reduction at week 12 was 130 points

                                                                 1. Feagan et al. Lancet Gastroenterol Hepatol 15-Jun 2020 online; 2. ITT-NRI analysis for SES-CD
                                         Investor Series Day 3   SES-CD=Simple Endoscopic Score for Crohn's Disease
                                                                                                                                                                                          Not for Product Promotional Use   14
Cendakimab: High unmet need in Eosinophilic
Esophagitis (EoE)
                                                                                Normal
                                                                              White exudates                 Longitudinal
• ~700K patients WW with EoE                                                   esophagus                       furrows
• Life-altering GI disease with significant patient burden
  — Inflammation progressing to fibrosis and narrowing of the esophagus
  — Patients experience reflux and nausea/vomiting
  — Risk of need for mechanical dilations to widen esophagus                   Fixed rings                     Strictures

• No FDA-approved therapies in the US today
  — Limited treatments options include diet, PPIs, and steroid formulations

• Cendakimab has the potential to be a differentiated new
  treatment option                                                               Edema                     “Crepe paper”
                                                                                                             esophagus
  — Targets the underlying inflammation and resulting fibrosis that lead to
    disease progression in EoE

                 Investor Series Day 3                                                       Not for Product Promotional Use   15
Cendakimab: Targets Key Cytokine in Pathogenesis of EoE

                                                                     • High affinity IL-13 neutralizing antibody
                Cendakimab
                                                                         ‒ Binds to the IL-13 ligand, thus inhibits
                                                                           binding to IL-13Rα1 and IL-13Rα2 subunits

       IL                              IL                            • Upregulated IL-13 is the key mediator of the
       13     Cendakimab inhibits      13                              EOE disease process1
                 IL-13 binding to
              IL-13Rα1 & IL-13Rα2                                        ‒ Helps eosinophil recruitment and activation
        X            subunits           X
                                                                         ‒ Disrupts epithelial barrier function
     IL-13Rα1                        IL-13Rα2                        • By inhibiting both α1 and α2 subunits,
                                                                       cendakimab offers the potential to address both
                                                                       inflammation and fibrosis2
   Inflammation                     Fibrosis &
                                    Remodeling

                                        1. Caldwell et al. Curr Opin Immunol 2017
            Investor Series Day 3       2. Fichtner-Feigl et al Nature Medicine VOLUME 12 NUMBER 1 ,2006
                                                                                                           Not for Product Promotional Use   16
Cendakimab Phase 2 EOE study
Meaningful reduction in eosinophil counts and endoscopic findings at Week 16
                                         Primary Endpoint:                                                                                    Secondary Endpoint:
                                      Mean Esophageal Eosinophil                                                                                Endoscopic EREFS
                                      Count (cells/hpf) at Week 16                                                                    (Edema, Rings, Exudate, Furrows score)
                                                                                                                                              Total Score at Week 16
                          140.0                                                                                       10.0                                                     9.4
                                                                           122.6
                                                                                                                              9.1                    9.0
                                                        116.7                                                          9.0
                          120.0
                                                                                                                                     7.9
 Mean Esophageal Eosinophil

                                                                                                                       8.0
                          100.0      92.4 90.3

                                                                                             Mean EREFS Total Score
                                                                                                                       7.0
     Count (cells/hpf)

                                                                                                                                                           P=0.0004                     P
Cendakimab: Acceptable Safety Profile in Phase 2 EoE study

                                                         Placebo   RPC4046 180 mg   RPC4046 360 mg
                                                         (N=34)        (N=31)           (N=34)
                                                          n (%)         n (%)            n (%)
Number of Subjects Experiencing >1 TEAE                  22 (65)       20 (65)               29 (85)
  Headache                                                5 (15)       5 (16)                 7 (21)
  Upper respiratory tract infection                       3 (9)        5 (16)                 5 (15)
  Arthralgia                                                0          4 (13)                  2 (6)
  Nasopharyngitis                                           0          3 (10)                  3 (9)
  Diarrhea                                                2 (6)        3 (10)                  2 (6)
  Nausea                                                  4 (12)        2 (7)                  3 (9)
  Dizziness                                               2 (6)        3 (10)                  1 (3)
  Sinusitis                                                 0          3 (10)                  1 (3)
Number of Subjects Experiencing >1 Injection Site TEAE    6 (18)       4 (13)                 9 (27)

                Investor Series Day 3                                               Not for Product Promotional Use   18
Cendakimab: Conclusions

• New targeted therapy with potentially differentiated efficacy and safety
  for treatment of EoE
• Proof of Concept established, with work ongoing to support initiation of
  Phase 3 program in EoE
• Evaluating multiple LCM opportunities based on mechanism centrally-
  involved in broad span of type 2 inflammatory fibrotic diseases

            Investor Series Day 3                                     Not for Product Promotional Use   19
Potential first- and/or best-in-class late stage assets with
   significant life cycle management opportunities
         Immuno-Oncology                             Hematology                             Cell Therapy                   Immunology & Fibrosis                         Cardiovascular
         Asset          Tumor Type                Asset          Indication             Asset           Indication                Asset           Indication            Asset           Indication

                           Bladder        Rebloyzl(2)                MDS            ide-cel(3)               MM                                   Psoriasis        FXIa               Thrombotic
                         Esophageal       (EMA)                      MF             (BCMA CAR T)                                                    PsA            Inhibitor(4)        Disorders
                           Gastric                                                                                          TYK2                     UC
                        Glioblastoma                                  MM                                  DLBCL
                                          Iberdomide                                                                        Inhibitor                CD
Opdivo,                Hepatocellular     (CELMoD agent)              SLE           liso-cel                FL
                                                                                                                                                    SLE
Yervoy                  Head & Neck                                                 (CD19 CAR T)           CLL
                                                                                                                                                     LN
(anti PD-1,              Melanoma
                                          CC-486                     AML                                   MCL
 anti CTLA-4)          Mesothelioma       (DNMTi)                    AITL                                                   Zeposia                   UC
                            NSCLC                                                   orva-cel                 MM
                          Prostate                                                  (BCMA CAR T)                            (S1P agonist)             CD
                                          CC-92480                    MM
                            Renal         (CELMoD agent)
                                                                                    bb21217(3)                              Cendakimab               EoE
                                                                                    (BCMA CAR T)             MM             (anti-IL-13)
                                          CC-93269                    MM
Relatlimab               Melanoma         (BCMA TCE)
(anti-LAG3)                                                                                                                 HSP47                 Fibrosis

                          Bladder                                                                                           Pegbelfermin
Bempegaldesleukin(1)                                                                                                                                NASH
(IL-2)
                         Melanoma                                                                                           (FGF-21)
                           Renal
                                                MF = myelofibrosis; MM = multiple myeloma; AML = acute myeloid leukemia; AITL = angioimmunoblastic T-cell lymphoma; PsA = Psoriatic arthritis;
                                                UC = ulcerative colitis; CD = Crohn’s disease; SLE = systemic lupus erythematosus; LN = lupus nephritis
                        Investor Series Day   3                                                                                                                  Not for Product Promotional Use 20
                                                1) In partnership with NEKTAR Therapeutics, 2) in partnership with Acceleron, 3) partnership with bluebird bio, 4) In partnership with J&J
Substantial unmet need persists
in thrombotic diseases
  Factor Xa inhibitors significantly improved efficacy                                            Combining Factor Xa inhibitors with anti-platelet
  and safety from previous SoC, yet further                                                       agents has been shown to improve outcomes but
  opportunity to reduce bleeding risk exists                                                      increased bleeding risk limits usage

             Up to 20% of patients don’t receive                                                       Inability to combine OACs with dual-antiplatelet
             anticoagulation, despite being at high stroke risk1                                       therapy for neurologic/cardiac conditions

             Many patients with AF receive doses lower than
             recommended, which may result in sub-optimal
             outcomes2,3

        Significant opportunity for an agent with comparable efficacy and reduced bleeding risk over
                                             Factor Xa inhibitors

1. McIntyre et al, Clin Card 2018; 2. Camm et al, EHJ suppl 2018; 3. Steinberg et al, JAHA 2018

                            Investor Series Day 3                                                                                   Not for Product Promotional Use   21
Factor XIa inhibition has the potential to prevent
thromboembolic events with a reduced risk of serious bleeding

            Intrinsic Pathway

     FXII                      FXIIa
                                                                                        Extrinsic Pathway

                                                                                                                              Vessel
                  FXI                  FXIa          BMS-986177                             Tissue Factor                     injury

                                FIX           FIXa                                  FVIIa                   FVII

                                                                                                   Apixaban                             Warfarin
                                                                                                   Rivaroxaban                          blocks FVII,
                          Common Pathway             FX                       FXa                                                       FIX, FX, and
                                                                                                   Edoxaban
                                                                                                                                        FII synthesis

                        Thrombin Feedback                     FIIa                          FII
                                                 Dabigatran
                                                                                                                                        FVIIa also
                                                 Fibrinogen          Fibrin                                                             activates FIX
                                                                                                                                        (not shown)

              Investor Series Day 3                                                                                Not for Product Promotional Use   22
Factor XIa is a validated target with demonstrated efficacy
and evidence for lower bleeding risk
    Genetics & Epidemiology                                                                   Preclinical
                                                                                                                       Thrombus Weight Reduction                 Bleeding Time
Hemophilia C is an inherited deficiency in FXI
                                                                                                                100                                                                         10
• Spontaneous bleeding is rare

                                                                                                                                                                                                 Fold Increase in
                                                                                             Percent Thrombus
                                                                                             Weight Reduction

                                                                                                                                                                                                  Bleeding Time
                                                                                                                 80                                                                         8
• Reduced risk of CV events                                                                                      60                                                                         6
                                                                                                                 40                                                                         4
                                                                                                                 20                                                                         2
Retrospective cohort study of 10,193 patients                                                                     0                                                                         0
including over 1200 with measured FXI deficiency:1                                                                    Aspirin
                                                                                                                       COX
                                                                                                                                  Clopidogrel
                                                                                                                                     P2Y12
                                                                                                                                                Abciximab
                                                                                                                                                 GPIIbIIIa
                                                                                                                                                               Factor        Factor
                                                                                                                                                             Xa Inhibitor XIa Inhibitor

Risk of CV events lower by                                Risk of VTE lower by                                                  Antiplatelets                     Anticoagulants

       48%                    43%                            61%        No VTE
                                                                        events                Clinical
    In patients           In patients with                In patients   In patients with
    with mild             moderate-to-                    with mild     moderate-to-
                                                                                             In a Phase 2 study of patients undergoing total
    deficiency            severe deficiency               deficiency    severe deficiency1   knee arthroplasty, reduction of circulating FXI via
    HR 0.52               HR 0.571                        HR 0.39                            antisense oligonucleotide provided superior
                                                                                             reduction of VTE vs. enoxaparin and appeared
1   Preis et al, Blood 2017 / 2 Büller et al, NEJM 2015
                                                                                             safe with respect to bleeding2

                                  Investor Series Day 3                                                                                                           Not for Product Promotional Use                   23
Two Phase 2 trials will inform future development path

                       Secondary Stroke Prevention (SSP) Study
                       FXIa inhibitor + clopidogrel + aspirin vs.
                       clopidogrel + aspirin in patients with acute
                       ischemic stroke or transient ischemic attack
                                                                      Anticipated Readouts
                       (N=2350)                                       starting in 2021
                                                                      will inform potential
                                                                      for Ph 3 expansion in
                       Total Knee Replacement (TKR) Study
                                                                      several indications
                       FXIa inhibitor vs enoxaparin in patients
                       undergoing elective total knee replacement
                       surgery
                       (N=1200)

        Investor Series Day 3                                                 Not for Product Promotional Use   24
Key takeaways
Ongoing Opportunity to Broaden Immunology Portfolio
• Differentiated TYK2i as best in class therapy for Psoriasis with broad potential
  in autoimmune diseases
• Expansion opportunities for Zeposia with LCM program
   — UC – positive Ph3 topline results
   — CD – ongoing Ph3 trial
 • Cendakimab is a potentially differentiated new treatment for EoE
   — Starting Ph3 late 2020 / early 2021

Important opportunity to renew our CV portfolio with Factor XIa
• Potential to broaden the use of antithrombotic therapy

              Investor Series Day 3                                                  Not for Product Promotional Use   25
Immunology & CV Commercial

                               Chris Boerner
                               Executive VP
                               Chief Commercialization Officer

       Investor Series Day 3                                     Not for Product Promotional Use   26
Strong foundation of in-line products with opportunities
for continued growth
  In-line Portfolio                        Future Growth Opportunities
  Strong commercial foundation including   Opportunity to grow the franchise with
  Zeposia early in its life cycle          new medicines and new indications

                                                      Zeposia IBD

                                                      Cendakimab

                                                         TYK2i

                                                       Factor XIa

           Investor Series Day 3                                     Not for Product Promotional Use   27
Immunology market and our near term opportunity
                                            BMS’ Marketed and Late Stage Medicine
Immunology Context                          Launches in Immunology

• BMS has created a successful model to                                                    EoE
  compete in the RA market                                                                 UC
                                               Selective TYK2i                         Crohn’s
• BMS built capabilities in targeted           Cendakimab                                Lupus
  patient identification, data generation                                                 PSA
  and access/reimbursement support                                                     Crohn’s
                                                                    PSO                   PSO
• Our success in Rheumatology builds a                              UC                     UC
  foundation for a broader set of                                  GvHD                  GvHD
  Immunology opportunities across Derm,          MS                 MS                    MS
  MS and GI                                      JIA                JIA                   JIA
                                                 PSA                PSA                   PSA
                                                 RA                 RA                    RA
                                                2020               2021-23             2024+
                                              (Marketed)         (Near Term)        (Long Term)

              Investor Series Day 3                                            Not for Product Promotional Use   28
Potential to establish a strong position
                            in relapsing Multiple Sclerosis (MS)

   Market: Multiple Sclerosis             Profile: Best-in-Class S1P          US Launch 2020

Large concentrated market with        Differentiated profile              • Approved March, Launched June 1
significant patient engagement        recognized by HCPs                  • Medical field-based presence
• >1M RRMS diagnosed prevalence WW    • High efficacy treatment,            since 2018
  (~360K US, ~415K EU5)                 comfortable with S1P mechanism    • Live and virtual visits, leveraging
• In US, 3K HCPs make up 80% TRx      • Advantages on safety profile vs     remove engagement capabilities
                                        other S1Ps and no first-dose CV   • Patient engagement and best-in-
• HCP treatment experience              monitoring
  drives treatment choice                                                   class patient support
                                      • Fewer tests (no ophthalmic or     • Strong access capability
• Strong patient involvement            genetic test required)
                                                                          • EU: July 15 Germany product
                                      • Strong brain preservation data      listing; HA reviews in CA, CH,
                                      • Once-daily dosing                   AUS

              Investor Series Day 3                                                        Not for Product Promotional Use   29
IBD: Building a Differentiated Portfolio
Our Opportunity In IBD                             U.S. EU5 Diagnosed IBD Patients (2020e)

• Large population, underserved by current          Patients (M)                     Crohn’s Disease
  therapy options                                                                    Ulcerative Colitis
   — Biologics (older TNFs and newer treatments)          ~3.1
     are injectables and have limitations
   — First novel oral (JAK) reserved only
     post-TNF for UC (US)                                  46%
                                                                        ~1.9
• Zeposia has the potential to be first-in-class
  S1P and expand oral pre- and post-biologic
  opportunity
                                                                                            ~0.8
                                                           54%
• Potential for a strong GI franchise with:
  — Zeposia Crohn’s Ph 3: enrolling now
  — TYK2i and pipeline medicines                        Diagnosed     Moderate-      On Biologics/
                                                        Prevalent     to-Severe       Novel Orals
                                                                      Prevalent        Prevalent
               Investor Series Day 3                                              Not for Product Promotional Use   30
Potential to Play an Important Role in
                          Ulcerative Colitis (UC)
UC Patients                                    Potential to expand the oral pre- and post-
• ~60% female; diagnosed around age 30         biologic market with first-in-class
                                               selective S1P
• Significant pain, flares, impact on all
  aspects of life and work                     • Clinically meaningful efficacy competitive
                                                 with existing novel treatments (biologics)
• Facing lifelong treatment, bowel resection
                                                 − Highly statistically significant and
                                                   consistent across clinical and
Relief with current options, but concerns:         endoscopic endpoints
• Prolonged steroid use                        • Differentiated safety profile
• Fear of injectable biologics (infections,       −Established safety (no black box
  malignancy)                                      warning) in MS with no cardiac
• Known JAK profile – black box warning            monitoring required
                                               • Convenient once-daily oral dosing
            Investor Series Day 3                                                Not for Product Promotional Use   31
Opportunity to build a differentiated GI franchise
Novel mechanisms across immunologic disorders and strong track record of commercial success

                    Establish GI franchise with Zeposia
                        — Positive topline in UC
                        — Enrolling Ph3 program in CD

                                          Broaden beyond IBD with Cendakimab in EoE
                        Cendakimab
                                            — Ph3 to start late 2020/early 2021

                                               TYK2i         Expand with TYK2i
                                                               — POC studies underway in UC and CD

            Investor Series Day 3                                                       Not for Product Promotional Use
                                                                                                                          32
BMS 986165                Moderate-Severe Psoriasis (PSO) will serve
(selective TYK2i)              as a platform for multi-indication LCM program
    Market:                                                                      Building a Dermatology
                                           Profile: Best Oral Option
    Moderate-Severe Psoriasis                                                    Franchise
 Significant opportunity to             HCP enthusiasm for profile (Ph2)       • High medical engagement
 expand oral market with                • Promising efficacy on skin
                                                                                 through Ph 3 enrollment
 best-in-class medicine                   clearance: superior to apremilast,   • Hire field sales and access
 • >3M diagnosed prevalence               comparable to TNFs                     teams following Ph 3 data
   (~1.7M US, ~1.5M EU5)
                                        • Opportunity to create new SOC as     • Expand existing BMS analytics,
 • Derms are largely safety conscious     pre-biologic treatment                 customer and medical
                                                                                 capabilities
 • Topicals are still widely used       • Novel mechanism differentiated
                                          from JAKs on safety
 •
Strong foundation of in-line products with opportunities
for continued growth
  In-line Portfolio                        Future Growth Opportunities
  Strong commercial foundation including   Opportunity to grow the franchise with
  Zeposia early in its life cycle          new medicines and new indications

                                                     Zeposia IBD

                                                     Cendakimab

                                                        TYK2i

                                                       Factor XIa

           Investor Series Day 3                                     Not for Product Promotional Use   34
Ability to Leverage History of Strong Commercial Execution

 Eliquis Net Sales                                                 Factor XIa: Potential to Continue CV Leadership
      WW Net Sales ($B)                                             • Consecutive CV alliances established Plavix &
                                                         $7.9
                                                  $6.4                Eliquis as SOC antithrombotic medicines
                                           $4.9
                                 $3.3                               • Eliquis provides platform for significant growth
                       $1.9
               $0.8
      $0.1                                                          • Factor XIa inhibitor (with Janssen) provides
      2013     2014    2015      2016      2017   2018   2019         opportunity for next-generation antithrombotic
                                                                      therapy for prevention and treatment of major
  #1         US Eliquis share Oral Anti-coagulant (OAC) market
             • NBRx: 57%, TRx: 47%
                                                                      thrombotic conditions

                                                                        — Monotherapy and/or combination with
             • Established Eliquis as the #1 OAC globally
             • Continue to grow novel oral anti-coagulant (NOAC)          antiplatelets
               and OAC shares 7 years post-launch
             • Focus on market expansion in key markets

                   Investor Series Day 3                                                              Not for Product Promotional Use   35
Key takeaways
Near-term opportunities
• Strong foundation with in-line portfolio
• Zeposia launched in MS with best-in-class profile (S1Ps) also enabling expansion
  into IBD with UC
• First-in-class TYK2i has potential to transform psoriasis treatment
• Opportunity to establish GI franchise with Zeposia, TYK2i, Cendakimab

Future opportunities
• LCM for Zeposia and TYK2i provide expansion into areas of larger unmet need
• Substantial unmet need remains in thrombotic diseases
   — Phase 2 trials (Secondary Stroke Prevention & Total Knee Replacement) will
     inform a range of Phase 3 development paths
             Investor Series Day 3                                          Not for Product Promotional Use   36
Financial Overview

                                David Elkins
                                Executive VP
                                Chief Financial Officer

        Investor Series Day 3                             Not for Product Promotional Use   37
Multiple Value Drivers

Strong in-line           8 near term          Robust LCM          6+ Next            Synergy
   business               launches             program           Medicines           Capture

                                   Significant financial flexibility

           Investor Series Day 3                                             Not for Product Promotional Use   38
Future outlook supported by launches, broad and deep
pipeline, and strategic business development
   Significant long-term commercial opportunities

     New Launches                   ~$20B* in revenue potential**               Inrebic • Reblozyl • Zeposia
                                    in 2H of the decade                         CC-486 • Liso-cel • Ide-cel • TYK2i

     Next Medicines                 6+ agents in or close to full               Relatlimab • CELMoD agents • Bempeg
                                    development; each with                      TCE (CC-93269) • Cendakimab • Factor XIa
                                    significant commercial
                                    potential**
     Next Wave                      Maturing early pipeline

   Strategic Business Development
   • Continue to source innovation and                                      • Enabled by financial strength & flexibility
     assets from outside the company                                           — Current balance sheet strength
*non-risk adjusted
                                                                               — Significant cash flow generation
**subject to positive registrational trials and health authority approval

                         Investor Series Day 3                                                                   Not for Product Promotional Use
                                                                                                                                                   39
Progress on integration: On track to achieve major
milestones and synergy goals

         Cultural                         Organizational                   Synergies
       Integration                           Strength

 • Aligned company vision,            • ~90% of the organization   • Consolidating sites
   mission & values                     in place globally            globally
 • Positive employee                  • Strong access to talent    • Progressing procurement
   engagement indicators                through presence in key      integration
                                        biopharma hubs
                                                                   • On track to deliver
                                                                     $2.5B by 2022 – 1/3
                                                                     expected in 2020

              Investor Series Day 3                                            Not for Product Promotional Use   40
Consistent approach to capital allocation

      Committed to reducing debt:
Significant flexibility to invest in innovation

~$19B    *
              Q1 2020 cash balance

                       ~$45B expected in free cash flow
                                                  over 2020-2022

             ~$10B                                        ~$12B                                                           ~$7B
             in debt                                      in dividend**                                                   in CVR
             maturities                                   paid out                                                        payment

  Increasing strength of the balance sheet and strong excess cash flow

                                 *Cash includes cash, cash equivalents and marketable securities; 75% of total cash is in the U.S.
         Investor Series Day 3   **Future dividend payouts illustrated using 2020 dividend rate and requires board authorization
                                                                                                                                     Not for Product Promotional Use   42
Business Development a top priority

• Business development important to source external innovation

• Consistent criteria for sourcing innovation externally:
    Strategically                  Scientifically   Financially
    Aligned                        Sound            Attractive

• Focused on therapeutic areas of interest
 Immuno-oncology ● Hematology ● Immunology ● Cardiovascular ● Fibrosis ● Neurology

           Investor Series Day 3                                      Not for Product Promotional Use   43
Financial strength of the company

           Multiple Value                               Consistent Approach
           Drivers                                      to Capital Allocation

         • Strong in-line business                 • ~$45B of expected free cash flow over
                                                     the next 3 years
         • 8 near term launches                    • De-levering to
Investor Series

                                Giovanni Caforio
                                Chairman and
                                Chief Executive Officer

        Investor Series Day 3                             Not for Product Promotional Use   45
Deep portfolio for continued innovation across key therapeutic
areas of focus
                                    Immuno-Oncology          Hematology         Immunology & CV

Inline
Brands

New
Launches                                              liso-cel   ide-cel   CC-486              TYK2i
                                1L Lung, CM-9ER

                       Metastatic disease                  Multiple myeloma          Inflammatory            Other
Multiple                                                                                 Bowel           auto-immune
                                                          B-cell malignancies           Disease             diseases
LCMs                  Early stage disease
                                                           Myeloid diseases           UC - Crohn’s   Lupus - Psoriatic arthritis

Next                 Relatlimab                            CELMoD agents                    Factor XIa inhib
Medicines
              Bempeg (NKTR-214)                        T-cell engager (TCE)                             Cendakimab

Next Wave   >20 assets with proof of concept decisions over the next three years
            Investor Series Day 3                                                                          Not for Product Promotional Use   46
Well positioned for the near-term and long-term

  “
 CURRENT       Leader with Strong Set of In-line Brands

      NEAR TERM                  Growth Driven by New Launches and LCM
                                 Expansion

                                     Sustainability Enabled by Internal Innovation
             LONG TERM
                                     and Business Development

         Investor Series Day 3                                          Not for Product Promotional Use   47
Q&A
      Giovanni Caforio, M.D.    Chris Boerner, Ph.D.
      Chairman,                 Executive VP,
      Chief Executive Officer   Chief Commercialization Officer

      David Elkins              Samit Hirawat, M.D.
                                Executive VP,
      Executive VP,
                                Chief Medical Officer,
      Chief Financial Officer   Global Drug Development

      Nadim Ahmed               Rupert Vessey, M.A., FRCP, D.Phil
      Executive VP,             Executive VP,
      President, Hematology     President, Research & Early Development

        Investor Series Day 3                                Not for Product Promotional Use   48
You can also read